What are treatment options for acute promyelocytic leukemia (APL) in patients younger than 60 years?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

However, a randomized study from France questioned this approach. [91] Newly diagnosed APL patients younger than 60 years with a WBC count of less than 10,000/µL were randomly assigned to receive either ATRA combined with and followed by three courses of daunorubicin plus cytarabine  and a 2-year maintenance regimen (cytarabine group) or the same treatment but without cytarabine (no-cytarabine group).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!